Interactions between Sle1 and other susceptibility loci were required for disease development in the NZM2410 model of lupus. Sle1 corresponds to at least three subloci, Sle1a, Sle1b, and Sle1c, each of which independently causes loss of tolerance to chromatin, but displays a distinctive immune profile. We have used congenic strains to analyze the interactions between the Sle1 subloci and other lupus susceptibility loci using Y autoimmunity accelerator (Yaa) and Fas lpr as sensitizing mutations. Sle1 coexpressed with either one of these single susceptibility alleles resulted in a highly penetrant nephritis, splenomegaly, production of nephrophilic antibodies, and increased expression of B-and T-cell activation markers. Here, we show that only Sle1b interacted with Yaa to produce these phenotypes, suggesting that Sle1b and Yaa belong to the same functional pathway. Interactions between the three Sle1 loci and lpr resulted in lymphocyte activation and lupus nephritis, but a significant mortality was observed only for the Sle1a.lpr combination. This suggests a major role for the FAS pathway in keeping in check the loss of tolerance mediated by the Sle1 loci, especially for Sle1a. Our results illustrate the complexity of interactions between susceptibility loci in polygenic diseases such as lupus and may explain the clinical heterogeneity of the disease.
Introduction
The clinical, pathologic presentation and course of systemic lupus erythematosus (SLE) is highly variable. Current hypotheses to explain this variability include genetic and environmental factors and their interactions. One consistent characteristic feature of SLE is the development of autoimmune responses to nuclear antigens. Linkage analyses in SLE patients and murine models have shown that multiple susceptibility genes are involved. 1 Congenic analysis of the NZM2410 lupusprone mouse has shown that individual susceptibility alleles have rather modest effects on various pathways of the immune system. 2, 3 Clinical disease occurs only when the number of susceptibility alleles exceeds a liability threshold, 3, 4 and the understanding of the interactions between these susceptibility alleles is the key to a successful gene-based therapeutic approach of SLE.
The NZM2410 Sle1 susceptibility locus results in the loss of tolerance to nuclear antigens. 2, 5 Analysis of polycongenic strains has shown that Sle1 is a necessary initiating step of the pathogenic cascade in the NZM2410 model. 6 The complexity of the Sle1 locus is greater than originally expected with at least three subloci Sle1a, Sle1b, and Sle1c resulting in the production of anti-chromatin autoantibodies and lymphocyte activation with variable penetrance and amplitude. 7 Initial analysis of activation markers and response to immunization suggested that Sle1a affects mostly T-cell functions, while Sle1b mostly affects B-cell functions, and that Sle1c affects both B and T cells. 7, 8 Each Sle1 sublocus may therefore contribute independently to the intrinsic B-and T-cell defects that we have shown to be associated with Sle1. 8 We have recently proposed that mutations in the complement receptor 2 gene, Cr2, are responsible for the Sle1c phenotypes, 9 and that Sle1b corresponds to mutations in a cluster of seven genes belonging to the CD2 family. 10 As the identification of genes corresponding to quantitative trait loci (QTLs) is becoming a reality for polygenic diseases in general, 11, 12 and for autoimmune diseases in particular, 13 the mechanisms by which these genes contribute to autoimmunity and interact with other susceptibility or resistance genes has yet to be established.
Epistasis constitutes an essential feature of polygenic diseases that accounts for the emergence of strong phenotypes from allelic variants with weak individual effects. [12] [13] [14] This hypothesis has been directly demonstrated by combining heterozygous null mutations of known genes involved in B-cell signaling 15 or pancreatic b-cell function. 16 Statistical evidence of epistasis between QTLs has been obtained in many genome scans in both human and animal models. Direct evidence of epistasis between QTLs and analysis of its functional consequences can be obtained, however, only through analysis of polycongenic strains combining the interacting loci, which is most likely the main reason why such data are still rare. The collection of congenic strains that we have produced with NZM2410-derived Sle loci constitutes an ideal model to dissect the contribution of epistasis to a complex disease. A detailed quantitative and functional evaluation of the epistasis can be conducted using the quantitative phenotypes that we have associated with susceptibility loci in these strains. 2, 5, 17, 18 Sle1 engages in complex interactions with SLE susceptibility loci, resulting in amplified phenotypes leading to clinical disease, 6, [19] [20] [21] and with resistance loci resulting in protection from autoimmune responses. 22 Combination of Sle1 with either Y autoimmunity accelerator (Yaa) or Fas lpr results in a highly penetrant clinical SLE, emphasizing the synergy between Sle1 and each of these genes. 6, 21 Yaa or Fas lpr are single loci/alleles that are associated with clinical lupus when expressed on the appropriate genomic background. 23, 24 They can be considered in our study as sensitizing mutations, a tool that has been suggested to facilitate gene discovery in linkage analyses of polygenic traits due to their ability to increase polygene penetrance and/or alter their genetic pathways. 25 Here 
Results
Clinical disease resulted from specific combinations between the Sle1 loci and Yaa or lpr Figure 1 shows the respective locations of the B6.Sle1 subcongenic intervals and their flanking markers. Confirming our earlier results, 6 B6.Sle1.Yaa mice developed clinical disease with 25 and 60% mortality at 6 and 9 months of age, respectively (Figure 2a) . Similar results were obtained with B6.Sle1ab.Yaa, but not with any of the single Sle1 loci combined with Yaa. In fact, the low mortality observed in B6.Sle1a.Yaa and B6.Sle1b.Yaa (13 and 14%, respectively) occurred before 2 months of age, and was probably associated with a high pre-or perinatal mortality that we have observed in B6.Sle1.Yaa mice as compared to their female littermates (Morel et al, unpublished) . As predicted, 21 B6.Sle1.lpr mice also showed a highly penetrant clinical disease, with 80% mortality by 6 months and 100% by 9 months of age (Figure 2b ). B6.Sle1ab.lpr mortality also reached 100% by 9 months of age, but it was significantly delayed as compared to B6.Sle1.lpr (48% at 6 months of age, w 2 ¼4.53, P¼0.03), indicating an effect from additional loci in the Sle1 interval, including Sle1c. The Sle1a locus was the only single locus associated with a significant mortality when combined with lpr (31 and 34% at 6 and 9 months of age). Overall, these results suggest that no single locus can account for the fatal clinical disease observed in both B6.Sle1.Yaa and B6.Sle1.lpr. It is instead the consequence of interactions of Yaa or lpr with more than one Sle1 locus: Sle1a and Sle1b for Yaa, and all three loci for lpr. In the strains combining a single Sle1 locus and Yaa or lpr, mortality is by definition epistatic, and not additive, since none of the single congenic strains, B6.Sle1a, B6.Sle1b, B6.Yaa, or B6.lpr, suffered any clinical disease. The extent of epistatic interactions occurring between Sle1a and Sle1b, when expressed with either Yaa or lpr, was quantified. At 9 months of age, mortality in B6.Sle1ab.Yaa mice was 50%, instead of 29% expected if the interaction was additive, and mortality in B6.Sle1ab.lpr mice was 100%, instead of 49% expected if the interaction was additive (Figure 2c) . These results clearly demonstrate that in these strains, the highly penetrant clinical disease results from epistatic interactions between multiple loci.
Mortality in the B6.Sle1ab and B6.Sle1 combinations with Yaa and lpr coincided with renal pathology and the incidence of proliferative glomerulonephritis (GN) (Figure 3a and in the NZM2410 model. 6 Lower levels of proliferative GN were found in B6.Sle1a.lpr and B6.Sle1c.lpr kidneys, but none in B6.Sle1a.Yaa and B6.Sle1c.Yaa. Sle1b was associated with a relatively high total and proliferative GN, and with immune complex deposition in both Yaa and lpr combinations (Figure 3c ). These two strains, however, suffered a very low mortality (Figure 2 ). On the other hand, B6.Sle1c.lpr kidneys showed low levels of immune complex deposits that were not significantly higher than B6.lpr. Yet, some mortality was observed in B6.Sle1c.lpr (Figure 2 ). These results show that renal pathology and fatal clinical disease do not correlate for some of the Sle1 combinations, suggesting that some pathogenic factors may be missing in these strains. As we have shown for mortality, epistatic rather than additive interactions between Sle1a and Sle1b accounted for the proliferative GN in B6.Sle1ab.Yaa mice (Figure 3d) . A much smaller epistatic effect (10%) was observed for proliferative GN in B6.Sle1ab.lpr mice, which may be due to a penetrance of 90% already achieved through additive interactions (Figure 3d ).
Sle1b expressed with either Yaa or lpr was associated with anti-dsDNA and nephrophilic antibodies The coexpression of Sle1 and Yaa resulted in the expression of anti-dsDNA IgG and nephrophilic antibodies (Abs), which are not induced by Sle1 alone. 6 Analysis of the individual Sle1 loci combined with Yaa revealed that Sle1b was the single locus associated with the largest anti-dsDNA Ab production (Figure 4a and b) . The effects of the Sle1b-Yaa interactions were clearly present at 3 months of age, which is earlier than antichromatin Abs production in B6.Sle1b. 7 Consequently, Yaa coexpression with Sle1b resulted in an epitope spreading of the autoantibody specificity, and in an acceleration of the loss of tolerance. We have previously shown that a similar phenomenon resulted from the combination of Sle1 and Sle3.
19 Sle1a alone was associated with low titers of anti-dsDNA Ab. The main effect of Yaa coexpression with this locus was an acceleration of the anti-nuclear Ab production, since similar levels were obtained in 3-month-old B6.Sle1a.Yaa and 6-month-old B6.Sle1a sera. The combination of Sle1b and, to a lesser extent, Sle1a, with Yaa resulted in epistatic interactions. In contrast, the level of anti-dsDNA Ab produced by B6.Sle1c.Yaa mice was totally accounted for by additive interactions ( Figure 4c ). As shown earlier for mortality and renal pathology, anti-dsDNA Ab production showed an epistatic interaction between the Sle1a and Sle1b loci coexpressed with Yaa ( Figure 4d ).
The same analysis was conducted with the Sle1.lpr subcongenic strains. Results obtained on 6-month-old sera were not informative due to the high levels of antidsDNA Ab contributed by the lpr mutation itself (data not shown). At 3 months of age, both B6.Sle1a.lpr and B6.Sle1b.lpr produced significantly more anti-dsDNA Ab than either the single Sle1 loci or lpr (Figure 4a ), but the penetrance was higher in B6.Sle1b.lpr than in B6.Sle1a.lpr (100 vs 50%, Fisher's exact test P¼0.051). Sle1c associated with lpr was not associated with any significant increase in anti-dsDNA Ab. As for the Yaa combinations, epistasis accounted for a large portion of anti-dsDNA Ab produced by B6.Sle1a.lpr and B6.Sle1b.lpr, but not B6.Sle1c.lpr mice (Figure 4c ).
The production of anti-glomerular basement membrane (GBM) nephrophilic Ab paralleled that of antidsDNA Ab (Figure 4e ). Sle1b combined with Yaa, and both Sle1a and Sle1b combined with lpr, resulted in anti-GBM IgG. Surprisingly, Sle1b by itself produced anti-GBM Abs, which has not been previously reported. These results show that the nephrophilic Abs, when produced by Sle1b, either by itself, or with Yaa or lpr, corroborated the immune complex deposit findings (Figure 3c ), but were not associated with clinical disease. Although anti-GMB Abs have been shown previously to be a good predictor of fatal renal disease in other models of animals and human diseases, 26 our results suggest the existence of other determinants of fatal clinical outcome that are not yet identified.
Yaa selectively enhances weak immune responses, and this effect depends on the BXSB genetic background. 27 Specifically, BXSB.Yaa males produce a strong IgG response to aggregated human IgG (HGG) as compared to B6.Yaa, in spite of a low responder H-2 b haplotype. Since interactions between Sle1b and Yaa resulted in autoimmune pathology, we tested whether B6.Sle1b.Yaa (also H-2 b ) produced the same high response to HGG. While B6.Yaa produced minimal amounts of anti-HGG IgG, a vigorous response was found in B6.Sle1b.Yaa (Figure 4f ). This result confirms that interactions between Sle1b and Yaa lead to major modifications of the immune system that are not limited to anti-dsDNA Ab production.
Specific combinations between the Sle1 loci and Yaa or lpr resulted in significant lymphocyte alterations Sle1a resulted in a significant spleen weight increase only when coexpressed with lpr, while Sle1b resulted in a significant increase with both Yaa and lpr (Figure 5a ). These increases resulted from epistatic interactions, as shown in Figure 5b . B6.Sle1ab.Yaa spleens were significantly larger than either B6.Sle1a.Yaa (P¼0.0005) or B6.Sle1b.Yaa (P¼0.05) spleens, which corresponded to an epistatic effect between Sle1a and Sle1b coexpressed with Yaa (Figure 5c ). This was not true for Sle1a and Sle1b coexpressed with lpr, for which only additive effects were observed. Interestingly, spleens in B6.Sle1c.Yaa mice were significantly smaller than in B6.Yaa, and tended to be smaller than in B6.Sle1c mice (P¼0.061), indicating a possible negative interaction between these loci. In support of this hypothesis, spleens in B6.Sle1.Yaa mice, which contained all three Sle1a, Sle1b, and Sle1c loci, were significantly smaller than in B6.Sle1ab.Yaa mice (P¼0.04). Finally, the combination of Sle1c and lpr did not result in increased spleen weight over the expression of lpr alone. Table 1 shows a compilation of the absolute numbers of the major lymphocyte subsets in the spleen. Differences in spleen size as shown above, and hence total cell numbers, obviously constitute a major factor in the differences in cell numbers in the various subsets. Specific relative differences were also found in specific locus combinations. The accumulation of CD3 þ CD4 À CD8 À (DN) lymphocytes is a characteristic of the lpr mutation. 23 Coexpression of either Sle1a or Sle1c significantly enhanced this process (Figure 6a ), while the proportion of DN T cells was similar between B6.Sle1b.lpr and B6.lpr mice (although their absolute number is increased in B6.Sle1b.lpr mice, as shown in Table 1 ). The B6.Sle1a.lpr and B6.Sle1c.lpr DN phenotype could not be accounted for by additive interactions, implying the existence of epistasis between these two Sle1 loci and lpr (data not shown). There was no significant difference between B6.Sle1a.lpr and B6.Sle1ab.lpr, confirming the absence of contribution of Sle1b to DN T cells accumulation. A significant increase in B7-2 expression was observed in B6.Sle1.Yaa B cells as compared to either B6.Sle1 or B6.Yaa (Figure 6b ). Only B6.Sle1b.Yaa mice showed a similar increase, which also corresponded to epistatic interactions (data not shown). Interestingly again, B7-2 expression in B6.Sle1c.Yaa B cells was significantly lower than in B6.Sle1c (Po0.05). Levels of B7-2 expression were uninformative in the lpr strains due to the large effect of the lpr mutation itself. As for B7-2 on B cells, CD69 expression levels on CD4 þ T cells were significantly increased in B6.Sle1b.Yaa mice (Figure 6c ). In the lpr combinations, both Sle1a and Sle1c resulted in a significant increase in CD69 expression, while CD69 was expressed at similar levels in both B6.lpr and B6.Sle1b.lpr on CD4 þ T cells. Interestingly, increased expression of CD69 in the lpr combinations could be fully accounted for by additive interactions (Figure 6d) .
Interactions between the Sle1 loci and Yaa resulted in monocytosis An age-dependent increase in the number of circulating monocytes, and, to a lesser extent, of spleen monocytes, has been reported in the lupus-prone mouse BXSB.Yaa. 28 This phenotype was dependent on the combined presence of Yaa and the BXSB background, as it was absent in both B6.Yaa males and BXSB females. B6.Sle1.Yaa mice accumulated significantly more CD11b þ peripheral blood lymphocytes (PBLs) and CD68 þ PBL and splenocytes than B6.Yaa by 6 months of age (Figure 7a and c) . A mixed population of cells is affected by the interaction between Sle1 and Yaa, with the largest increase occurring in the macrophage and B1 cell populations (Tables 1 and 2 ). B6.Sle1.Yaa monocytes also expressed significantly more MHC class II molecules (Figure 7d ) and tended to express more CD40 (data not shown). These results indicate that the Sle1-Yaa interactions not only increased the number of monocytes but Genetic interactions in murine lupus BP Croker et al also their activation level. Monocyte numbers and activation levels in 2-month-old B6.Sle1.Yaa were similar to that of B6.Sle1 or B6.Yaa mice at either 2 or 6 months of age (data not shown). This showed that, as in BXSB.Yaa, monocytosis in B6.Sle1.Yaa mice is age dependent and requires the interactions between Yaa and other genetic factors. The significance of the higher proportion of CD19 þ CD11b þ cells in B6.Sle1.Yaa (Figure 7d ) is unclear. This phenotype has been described for peritoneal B1a cells, but not for splenic B1 cells. 29 Since these cells are CD5 þ in the B6.Sle1.Yaa mice, our results suggest that these CD19 þ CD11b þ cells belong to the B1a subset. This phenotype has not been evaluated in BXSB.Yaa, and we cannot predict whether this strain also develops an increased CD19
We mapped the locus responsible for B6.Sle1.Yaa monocytosis with the four Sle1-Yaa substrains. B6.Sle1a-b.Yaa monocytes were identical to B6.Sle1.Yaa, while B6.Sle1c.Yaa phenotypes were identical to those of B6.Yaa (data not shown), suggesting that Sle1a and/or Sle1b may be responsible for these phenotypes. In fact, both B6.Sle1a.Yaa and B6.Sle1b.Yaa showed intermediate phenotypes, with CD68 þ expression levels in the spleen equivalent to that of B6.Sle1.Yaa, but equivalent to B6.Yaa in PBL (Figure 7b and c) . Increased absolute cell numbers were much more dramatic in B6.Sle1b.Yaa than in B6.Sle1a.Yaa (Table 2) , which corresponds to the spleen weight in these respective strains. I-A b and CD19 expression on CD11b þ PBL in B6.Sle1a.Yaa mice was equivalent to B6.Sle1.Yaa, while B6.Sle1b.Yaa was equivalent to B6.Yaa (Figure 7b and d) . These results showed that B6.Sle1.Yaa monocytosis resulted from interactions between both Sle1a and Sle1b with Yaa, with Sle1a possibly playing a larger role.
Discussion
One of the challenges presented by multigenic diseases such as SLE is to understand how interactions between susceptibility genes lead to clinical pathogenesis. We have dissected the interactions between the Sle1a, Sle1b, and Sle1c loci identified by their association with the loss of tolerance to chromatin, 7 and two single loci associated with systemic autoimmunity, Fas lpr22 and Yaa. 23 The identity of Yaa is still unknown due to its position on the Y chromosome, but chimera analyses have shown that it is most likely a B-cell gene that modulates B-T-cell interactions. 30, 31 We showed here that Sle1 plays a similar role as the BXSB or the MRL background in potentiating the autoimmune effects of the Yaa and lpr alleles, respectively, to produce a highly penetrant autoimmune pathology leading to fatal nephritis. We also showed that Sle1 could substitute for BSXB in two Yaa-mediated phenotypes: monocytosis 28 and humoral response to weak antigen. 27 Each of the three Sle1 loci had, however, a different contribution to this process, which is summarized in Table 3 . Our data also provided functional evidence on the specific epistatic interactions between each of the Sle1 loci and Yaa, or lpr, and also evidence of epistasis between Sle1a and Sle1b.
Sle1b was the major contributor to the B6.Sle1.Yaa phenotypes. Renal pathology, autoantibody production, immune complex deposition, splenomegaly, increased Band T-cell activation, and enhanced humoral response to weak antigens were observed in B6.Sle1b.Yaa, but not in B6.Sle1a.Yaa or B6.Sle1c.Yaa. By analogy to classical genetic dissections, or to more recent combinations of heterozygous null alleles, 15, 16 our data suggest that Sle1 and Yaa belong to the same functional pathway in that their coexpression results in epistasis. Recent findings demonstrating that Sle1b is a member of the SF cluster, which is composed of CD2-family members, B-cellexpressed genes regulating interactions with T cells, 10 are in agreement with hypothesis. The elusive nature of the Yaa gene challenges, however, the formal proof of this hypothesis. Recent work based on the combinations between Sle1, Yaa, and FcRIIB À/À already suggested that these three loci belong to the same functional pathway. 20 Our own results provide evidence that this hypothesis applies only to Sle1b. Although no significant autoimmune effect was produced by the Sle1a-Yaa combination, a marked synergy between Sle1a and Sle1b was observed when combined with Yaa for several phenotypes. These interactions culminated in a highly penetrant nephritis in B6.Sle1ab.Yaa, which was not present in either B6.Sle1a.Yaa or B6.Sle1b.Yaa. Two conclusions can be drawn from these findings. First, the large amounts of autoantibodies normally associated with pathogenicity and the deposition of immune complexes in the kidneys in B6.Sle1b.Yaa and to a lesser extent in B6.Sle1a.Yaa mice were not sufficient to produce clinical disease. Similar results were also obtained for the B6.Sle1b.lpr combination. Such a dichotomy has previously been found in two different knockout models, the FcRg À/À32 and the Factor B-deficient MRL.lpr 33 mice. Second, Sle1a contributes to B6.Sle1.Yaa pathogenicity most likely through its interactions with Sle1b, which we have previously reported, 7 rather than through its interaction with Yaa, which does not affect the same phenotypes. Our initial findings that Sle1a affects mostly T cells and Sle1b B cells 7 and that Sle1b is a gene affecting T-B interaction 10 give functional support to the epistatic relationship between these two loci.
Interestingly, both Sle1a and Sle1b combinations with Yaa also resulted in increased monocyte numbers and activation status, although the contribution of monocytosis to Yaa-associated pathology is unknown. Our results suggest that there is no direct causal relationship, since B6.Sle1a.Yaa mice do not display a typical lupuslike autoimmune clinical disease. It is possible that Sle1a.Yaa-induced monocytosis indirectly contributes to the more established lupus phenotypes in B6.Sle1ab.Yaa or B6.Sle1.Yaa. In BXSB.Yaa, monocytosis results from an increased number of myeloid stem cells in the BXSB strain and a Yaa-induced age-dependent expansion of the monocytes produced from these stem cells. 34 Sle1a may also produce an increased number of myeloid stem cells, which is currently under investigation. All three Sle1 loci significantly interact with lpr, but it results in clinical disease only in the Sle1a.lpr combination. Most of the interactions between Sle1a, Sle1c, or Sle1b and lpr were epistatic. Epistasis was also present between Sle1a and Sle1b coexpressed with lpr, although to a lesser extent than with Yaa. One of the reasons for this difference may be the stronger phenotypes associated with B6.Sle1a.lpr and B6.Sle1b.lpr, suggesting that epistasis may be more detectable between weaker phenotypes. The notorious absence of epistasis for CD69 expression on helper T cells in the lpr combinations is unclear. It may be due to a ceiling effect, in which the simple additive interaction already resulted in a nearmaximal expression. Our results suggest that the Sle1 loci induce by themselves a strong autoimmune response, which is largely controlled by FAS-mediated tolerance pathways. In the absence of FAS, the full potential of the Sle1 loci is revealed, resulting in pathogenic responses. Sle1b, which is the strongest of the Sle1 loci, was the least amplified by lpr, suggesting that Sle1b-mediated autoimmunity is the least FAS dependent. It is interesting that the effects of the Cr2 À/À mutation, which we proposed to be allelic to Sle1c (9), were also greatly enhanced by the lpr mutation. 35 All the studies that have been conducted in polygenic diseases have suggested that clinical diseases result from interactions between loci that have by themselves weak nonpathogenic phenotypes. 13, 14 Unraveling the mechanisms of these interactions is the key to understanding autoimmune pathogenesis. Statistical modeling of interactions 14, 36, 37 has pointed out their limitations, largely because too many assumptions have to be made about unknown variables. Our result showed that the combination of congenic strains with potent single susceptibility genes constitutes a powerful tool to analyze interactions based on functional data. Yaa and lpr as sensitizing mutations were very effective for functional analysis of epistasis in congenic strains. These alleles not only increased the penetrance of the specific Sle1 phenotypes but also revealed different functional pathways. These characteristics of Yaa and lpr in our system correspond to the predicted functions of sensitizing loci. 25 A large number of gene-targeted mutations produce strong, well-characterized phenotypes, which could be used in a similar way to help in the analysis of susceptibility loci that have been isolated on congenic strains on the same genomic background.
Our results support the genetic hypothesis as a significant contribution to variable SLE expression and suggest that the complexity of interactions may be best described as a network of epistatic interactions in contrast to a linear additive model. The extent of epistasis among human SLE susceptibility alleles is largely unknown. However, it is very likely that a similar level of complexity to what we describe here for Sle1 is achieved by some human susceptibility alleles. Our results showed that genes with similar primary outcomes, such as a loss of tolerance to chromatin, may engage in specific interactions that led to distinct clinical outcomes. This may explain some of the heterogeneity of presentation of this disease.
Materials and methods
Mice C57BL/6J (B6), B6.MRL-Tnfrsf6 lpr (B6.lpr), and B6.SB-Yaa (B6.Yaa) mice were obtained from the Jackson Laboratory (Bar Harbor, ME, USA), and bred at the University of Florida. Production of the B6.Sle1 38 and its subcongenic strains (B6.Sle1a, B6.Sle1b, and B6.Sle1c, and B6.Sle1ab combining the two loci Sle1a and Sle1b) 7 and B6.Sle1.Yaa 6 has been previously described. The B6.Sle1.Yaa subcongenic strains were produced by breeding females from each of the four B6.Sle1 subcongenic strains with B6.Yaa males, then backcrossing the F 1 males to the corresponding B6.Sle1 subcongenic females. Homozygosity across the Sle1 subintervals was assessed by PCR with the corresponding microsatellite markers shown in Figure 1 , as described previously. 7 The B6.Sle1.lpr strains were produced by intercrossing (B6.Sle1 Â B6.lpr)F 1 hybrids for each of the five Sle1 subcongenic strains and selecting simultaneously for homozygosity at the corresponding Sle1 subinterval with the markers indicated in Figure 1 , and the lpr mutation (Fas forward primer: CAAGCCGTGCCCTAGGAAACACAG; reverse primer: GCAGAGATGCTAAGCAGCAGCCGG; and a reverse primer specific for the lpr allele: GTGGAGCTCCAATG CAGCGTTCCT). Nine new strains were produced, and a total of 15 mono-and bicongenic Sle1 strains were used in this study. The five monocongenic B6.Sle1 strains used as controls will be referred to as 'wild type' (wt), as opposed to their bicongenic counterparts carrying either the Yaa or the lpr locus. All mice, including B6.Yaa and B6.lpr, were maintained under identical conditions in conventional housing up to 9 months of age. By definition, all Yaa-carrying mice are males. Both males and females from the B6.Sle1.lpr strains were used. All mice from Sle1.Yaa or Sle1.lpr combinations used in this study were age and sex matched both with the corresponding B6.Sle1 strain, and with B6.Yaa or B6.lpr, respectively.
Serology
Sera were screened for anti-dsDNA IgG Ab at 3 and 6 months of age by ELISA as previously described.
2 Anti- þ splenocytes (see Figure 4c for details). For clarity, B6.Sle1a.Yaa and B6.Sle1c.Yaa, which did not increase in expression, were not shown. All mice were 6 months old, with 15 males and five females for each wt strain, 10 males for each Yaa strain, and five males and five females for each lpr strain. *Po0.05, **Po0.01, ***Po0.001.
GBM or nephrophillic Abs were assessed in 6-month-old sera as described previously. 39 
Flow cytometry
Flow cytometry was performed on at least 10 6-monthold mice per strain as previously described. 7 PBL were isolated by centrifugation with Lympholyte-Mammal (Accurate Chemical and Scientific Co, Westbury, NY, USA). The following primary Abs: RA3-6B2 (CD45R/ B220), 145-2C11 (CD3e), RM4-5 (CD4), 53-6.7 (CD8a), H1.2F3 (CD69), GL1 (CD86/B7.2), AF6-120.1 (I-A b ), 3/23 (CD40), M1/70 (CD11b), 1D3 (CD19), and RB6-8C5 (Ly-6G /GR1) were purchased from BD Pharmingen (San Diego, CA, USA). Anti-CD68 (FA-11) was purchased from Serotec (Raleigh, NC, USA). The CD68 levels were determined by intracellular staining in fixed permeabilized cells using the Cytofix/Cytoperm Plus kit (BD Pharmingen).
Histology GN was scored on multiple sections on a semiquantitative 0-4 and qualitative scale as previously described. 6 IgG and C3 immunofluorescence staining was performed as previously described 18 on frozen kidney sections using goat anti-mouse IgG (H þ L) FITC-conjugated (Southern Biotech., Birmingham, AL, USA) or goat anti-mouse C3 FITC-conjugated (ICN, Costa Mesa, CA, USA). Staining was quantified on two semiquantitative scales assessing distribution (0-4) and intensity (0-3) of the deposits in the mesangium. In addition, capillary staining was quantified on a 1-4 scale, where 1 indicates the absence of capillary deposits. In this study, all animals with capillary wall staining were also positive for mesangial staining. A DIC (distribution Â intensity Â capillary) index was computed by multiplying the three scores for each mouse (minimum: 0; maximum: 48). The DIC index for each locus combination was then averaged among five 6-monthold mice. All histology data were scored in a blind manner.
In vivo immune response Immune response to HGG was evaluated in B6.Yaa and B6.Sle1b.Yaa mice as previously described. 27 Briefly, 400 mg of heat-aggregated HGG (Sigma) in PBS was injected i.p. into four 8-week-old males per strain. Anti-HGG IgG was detected by ELISA on days 0 and 20 postinjection in 1:100 diluted sera in duplicate.
Statistical analysis
To assess the existence of significant interactions between a given Sle1 locus and Yaa or lpr, phenotypes were compared between mice carrying both loci and mice carrying them separately. Unless indicated, the mean and standard errors are shown and equal variance t-tests were used. Percentages were compared used w 2 tests. The average and standard error in million cells are shown for five mice per strain at 6 months of age 
